These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36443602)

  • 21. Breast, prostate, and thyroid cancer screening tests and overdiagnosis.
    Jung M
    Curr Probl Cancer; 2017; 41(1):71-79. PubMed ID: 28104314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Participation in organized screening for bowel cancer and screening for prostate cancer].
    Berchi C; Launoy G
    Sante Publique; 2019; S2(HS2):19-32. PubMed ID: 32372576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two conflicting guidelines on prostate specific antigen screening in Japan.
    Takahashi T
    Jpn J Clin Oncol; 2023 Mar; 53(3):280-283. PubMed ID: 36533417
    [No Abstract]   [Full Text] [Related]  

  • 27. [Not Available].
    Larsson LT; Kain J; Bratt O
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29437198
    [No Abstract]   [Full Text] [Related]  

  • 28. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission.
    Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
    Eur Urol; 2021 Mar; 79(3):327-329. PubMed ID: 33384200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening.
    Takahashi T
    World J Urol; 2024 Mar; 42(1):167. PubMed ID: 38492072
    [No Abstract]   [Full Text] [Related]  

  • 30. [Indirect consequences of PSA testing for prostate cancer screening].
    Naïmi R; Senglet M; De Gorski A; Kherad O
    Rev Med Suisse; 2020 Feb; 16(680):275-277. PubMed ID: 32022494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
    Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
    Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
    BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How should PSA screening efforts be focused to prevent underdiagnosis and overdiagnosis of prostate cancer?
    Pelzer AE; Horninger W
    Nat Clin Pract Urol; 2008 Apr; 5(4):172-3. PubMed ID: 18317497
    [No Abstract]   [Full Text] [Related]  

  • 34. Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.
    Gulati R; Feuer EJ; Etzioni R
    Am J Epidemiol; 2016 Jul; 184(2):140-7. PubMed ID: 27358266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
    Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
    J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
    Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
    BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overdiagnosis and overtreatment of prostate cancer.
    Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
    Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for prostate cancer: an updated review.
    Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing perceived clarity of information on overdiagnosis used for breast and prostate cancer screening in England: an experimental survey.
    Ghanouni A; Renzi C; McBride E; Waller J
    BMJ Open; 2017 Aug; 7(8):e015955. PubMed ID: 28827249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    Nyame YA; Gulati R; Heijnsdijk EAM; Tsodikov A; Mariotto AB; Gore JL; Etzioni R
    J Natl Cancer Inst; 2021 Oct; 113(10):1336-1342. PubMed ID: 33963850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.